427 participants
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-28
- Start Date:
- 2007-12-01
- Completion:
- 2015-01-01
Conditions
- Colorectal Neuroendocrine Tumor G1
- Gastric Neuroendocrine Tumor G1
- Neuroendocrine Neoplasm
- Neuroendocrine Tumor
- Neuroendocrine Tumor G2
Interventions
- BIOLOGICAL
- OTHER
- DRUG